PLGA polymers are biodegradable, widely available, and approved by regulatory agencies such as the FDA
PLGA particles for delivery of several different agents are on the market
PLGA particles can be administered via various routes
PLGA particles may decrease toxicity of vaccine components
Particle size, surface, and/or release characteristics can be tailored
PLGA particles allow controlled antigen release
PLGA particles protect antigen from degradation and elimination
PLGA particles enhance antigen uptake by APCs by mimicking size and shape of pathogens
PLGA particles enhance and prolong antigen cross-presentation efficiency
PLGA particles allow concomitant delivery of multiple vaccine components
Large surface area and surface functional groups allow conjugating of targeting moieties
PLGA particles may lead to antigen dose sparing
|
Negative charge of PLGA particles is disadvantageous for particle uptake
PLGA particle preparation process must be tailored to the properties of the antigen
PLGA particles cannot be sterile filtered
Antigen degradation may occur during preparation, storage, and release
Antigen release is often incomplete
Particle aggregation may occur
Particle size may limit crossing of biological barriers
|